These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16305286)

  • 21. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
    McKinnon PS; Paladino JA; Schentag JJ
    Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aerosol-based efficient delivery of clarithromycin, a macrolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections.
    Togami K; Chono S; Morimoto K
    J Aerosol Med Pulm Drug Deliv; 2012 Apr; 25(2):110-5. PubMed ID: 22360316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of pH on the in vitro activity of and propensity for emergence of resistance to fluoroquinolones, macrolides, and a ketolide.
    Dalhoff A; Schubert S; Ullmann U
    Infection; 2005 Dec; 33 Suppl 2():36-43. PubMed ID: 16518710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses?
    Theuretzbacher U
    Curr Opin Pharmacol; 2007 Oct; 7(5):498-504. PubMed ID: 17616438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macrolides: present and future. An appraisal of in-vitro activity and pharmacokinetic behavior.
    Furneri PM; Nicoletti G
    J Chemother; 1991 Jan; 3 Suppl 1():24-7. PubMed ID: 12041776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment options in odontogenic infection.
    Maestre-Vera JR
    Med Oral Patol Oral Cir Bucal; 2004; 9 Suppl():25-31; 19-24. PubMed ID: 15580134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical basis of macrolides apply in diseases of the respiratory tract].
    Płusa T
    Pol Merkur Lekarski; 2008 Nov; 25(149):432-6. PubMed ID: 19177783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and antibacterial activity of isomeric 15-membered azalides.
    Alihodzic S; Fajdetic A; Kobrehel G; Lazarevski G; Mutak S; Pavlovic D; Stimac V; Cipcic H; Kramaric MD; Erakovic V; Hasenöhrl A; Marsic N; Schoenfeld W
    J Antibiot (Tokyo); 2006 Dec; 59(12):753-69. PubMed ID: 17323642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection.
    Scaglione F; Paraboni L
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):479-90. PubMed ID: 16771624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and pharmacodynamics of gamithromycin in pulmonary epithelial lining fluid in naturally occurring bovine respiratory disease in multisource commingled feedlot cattle.
    DeDonder KD; Apley MD; Li M; Gehring R; Harhay DM; Lubbers BV; White BJ; Capik SF; KuKanich B; Riviere JE; Tessman RK
    J Vet Pharmacol Ther; 2016 Apr; 39(2):157-66. PubMed ID: 26441021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Macrolide antibiotics as biological response modifiers.
    Rubin BK; Tamaoki J
    Curr Opin Investig Drugs; 2000 Oct; 1(2):169-72. PubMed ID: 11249569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Blood and respiratory diffusion of antibiotics. A critical analysis of predictive parameters for clinical effectiveness].
    Fantin B
    Med Mal Infect; 2006; 36(11-12):599-613. PubMed ID: 16837154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics, pharmacodynamics, and Monte Carlo simulation: selecting the best antimicrobial dose to treat an infection.
    Bradley JS; Garonzik SM; Forrest A; Bhavnani SM
    Pediatr Infect Dis J; 2010 Nov; 29(11):1043-6. PubMed ID: 20975453
    [No Abstract]   [Full Text] [Related]  

  • 35. C-9 Alkenylidine bridged macrolides: WO2008061189. Enanta Pharmaceuticals, Inc.
    Poce G; Cesare Porretta G; Biava M
    Expert Opin Ther Pat; 2009 Jun; 19(6):901-6. PubMed ID: 19473109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A stochastic assessment of the public health risks of the use of macrolide antibiotics in food animals.
    Hurd HS; Malladi S
    Risk Anal; 2008 Jun; 28(3):695-710. PubMed ID: 18643826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Part VII. Macrolides, azalides, ketolides, lincosamides, and streptogramins.
    Dang V; Nanda N; Cooper TW; Greenfield RA; Bronze MS
    J Okla State Med Assoc; 2007 Mar; 100(3):75-81. PubMed ID: 17432033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [An example of simulation for a better understanding of PK/PD relationship of antibiotics].
    Le Normand Y; Ganiere-Monteil C; Drugeon H; Abbas S; Mazeas M; Kergueris MF
    Pathol Biol (Paris); 2004 Dec; 52(10):597-601. PubMed ID: 15596309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of inducible nitric oxide synthase expression and nitric oxide production by macrolide antibiotics in sulfur mustard-exposed airway epithelial cells.
    Gao X; Ray R; Xiao Y; Ray P
    Basic Clin Pharmacol Toxicol; 2008 Sep; 103(3):255-61. PubMed ID: 18684233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Macrolide and ketolide resistance with Streptococcus pneumoniae.
    Doern GV
    Med Clin North Am; 2006 Nov; 90(6):1109-24. PubMed ID: 17116439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.